Echo | Angio | ECG | X-Ray/MRI | Clinical Trials | Guidelines | Drug Info |  Journals  | Events | Interesting Cases

Welcome May 20, 2013
Search News by Date
  



Excellent post-transplant outcomes with mechanical circulatory support as bridge to heart transplantation

Studies have recently highlighted the conflicting results regarding the effects in the use of Ventricular assist devices (VADs), as a bridge to heart transplantation (BTT) especially on the post-transplant outcomes.  Addressing this issue, Dr. N Selimovic and coworkers performed the present study of their single centre experience that compared patients who underwent VADs with the patients who underwent heart transplantation (HTx) during the same period.

Study population consisted of 71 consecutive patients who received 73 VADs at researchers University Hospital (among them 68 accepted to receive a BTT had mean age 40 ± 18 years, and 15 % were females; remaining 3 were accepted for a destination therapy) from January 1997 through December 2011. These patients were compared with 40 matched controls, who underwent heart transplantation (HTx) during the same period.

Among the 68 patients, VAD implanted were as follows: 86 % had left-VAD; 11% had bi-VAD; and in 3% it was right-VAD.  2 patients were implanted with a total artificial heart.

Findings from this study showed 14 patients with VADs (16%) implanted had died, 3 patients recovered with device explanation and 51 patients were bridged with VADs to HTx. 133 days (range 3-1002 days) of median duration of VAD support was reported.

Additionally, it was found that the actual mortality on device support was 14 % while 46% of patients underwent an HTx.  40 non-bridged transplanted patients (mean age 45±16 years, 10% female) were compared. Similar 1, 3, and 5 years survival was reported between VADs patients and controls after HTx (1 yr survival; 84 vs. 92%, p=0.14; 3 yrs survival; 79 vs. 83%, p=0.11; 5yrs survival: 75 vs. 74 %, p=0.3, Figure)

Figure: 1, 3, and 5 years survival among Ventricular assist devices patients and controls after heart transplantation

In conclusion this study demonstrated that mechanical circulatory support as bridge to heart transplantation results in excellent post-transplant outcomes and the survival was similar to non- bridge to heart transplantation patients.

 


Source:HEART FAILURE 2012
Compiled and edited by the Editorial team and approved by Expert panel of CardioValens.com

 Other News
First study to evaluate the effectiveness of Functional Electrical Stimulation on exercise capacity, endothelial function and echocardiographic indices of diastolic function in chronic heart failure patients with preserved systolic function
Higher predictive value for malignant ventricular arrhythmias and complex end point for patients with dilated nonischaemic cardiomyopathy and chronic heart failure
Association between hyperglycemia and adverse outcomes observed in AMI patients does not hold true in patients hospitalized with other cardiovascular conditions
Presence of septal asymmetric Hypertrophic cardiomyopathy type is the only independent predictor of increased right atrial volume index
Significantly decreased degree of mitral regurgitation or an improved mitral regurgitation, reverse remodeling of left atrium and decrease in left atrium diameters are the benefits with cardiac resynchronization therapy
Myocardial lipid content correlates inversely with left ventricular function in heart failure patients with type 2 diabetes
Periodic use of levosimendan in outpatients with end-stage chronic heart failure is safe and effective in improving quality of life and in reducing re-admissions for worsening heart failure at least in the first eight months of therapy
Highly prevalent severe interatrial mechanical delay in heart failure with preserved ejection fraction is associated with shorter mitral A wave and higher filling pressures
Presence of microalbuminuria is a potential risk marker of events in patients admitted with ACS
The CARILLION® Mitral Contour System implanted in heart failure patients with functional mitral regurgitation provide clinical improvements
Digoxin in high risk Heart Failure patients with reduced ejection fractions
Co-relation between blood pressure/body composition and exercise in hypertensive older overweight individuals
Gender wise analysis of hypertensive patients under a stabilized therapy and without a history of cardiovascular events shows significant differences in the prediction of either stroke or global cardiovascular events or even both
Hygia Project: ingestion of full doses of hypertension medications at bedtime is a proper chronotherapeutic approach and shown to result in improved ambulatory BP control and fewer cardiovascular events
ARB-based aggressive antihypertensive therapy guided by home BP monitoring in patients with diabetes/pre-diabetes is effective in improving cardiovascular target damage
Hypoadiponectinemia and high aldosterone levels in arterial rigidity are responsible for resistance to an antihypertensive therapy
Total cholesterol control can be predicted by only younger age for management of childhood dyslipidemia and hypertension and prevention
Impact of the Combination Antihypertensive Therapy with inclusion of Atorvastatin and Metformin on insulin resistance parameters in patients with the metabolic syndrome and fasting hyperinsulinemia
The combination treatment with Telmisartan, Torasemid and Atorvastatin has positive effects on blood pressure levels and reduces the intensity of heart failure progression in hypertensive's with heart failure class II-III NYHA
Subjects with masked hypertension have an early alteration of diastolic dysfunction
Associations of an increasing plasma insulin levels in patients with metabolic syndrome and post-infarction cardio-sclerosis
Reflected pressure waves in the arm in contrast to central systolic BP do not contribute to the measured arm cuff systolic BP measurements except in Stage 2 hypertension and thereby do not typically influence the diagnosis or staging of systolic hypertension

About Us | Disclaimer |  Privacy Statement | Advertising Info 
info@centrixhealthcare.com © Copyright 2000-2013 Centrix Healthcare Inc. - All Rights Reserved.